Related Experiment Video
Updated: May 15, 2026
08:41
Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
Published on: January 12, 2016
Caspase-3 as a therapeutic target for heart failure
1The University of Hong Kong, Department of Pharmacology and Pharmacy, Level 2, Laboratory Block, LKS Faculty of Medicine Building, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.
Expert Opinion on Therapeutic Targets
|January 9, 2013
Summary
Targeting apoptosis, the programmed cell death of heart cells, offers a novel strategy for treating heart failure. Inhibiting caspase-3 may restore cardiac function and prevent disease progression.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Heart failure presents a significant global health challenge with high mortality rates.
- Aging populations exacerbate heart failure prevalence, demanding effective therapeutic interventions.
- Cardiomyocyte loss through apoptosis is a key mechanism in heart failure pathogenesis.
Purpose of the Study:
- To review the evidence supporting anti-apoptotic strategies for heart failure.
- To explore the potential of targeting apoptosis for cardiac dysfunction reversal.
- To highlight the role of caspase-3 inhibition in heart failure treatment.
Main Methods:
- Review of existing scientific literature on apoptosis in heart failure.
- Analysis of studies investigating the effects of apoptosis inhibitors.
- Examination of the role of caspase-3 in cardiac pathophysiology.
Main Results:
- Apoptotic cardiac cells may retain the potential for functional recovery.
- Inhibiting apoptosis can improve systolic function and reverse cardiac remodeling.
- Caspase-3 inhibitors demonstrate promise in interrupting apoptosis in heart tissue.
Conclusions:
- Antiapoptotic therapy presents a novel, albeit complex, approach to heart failure management.
- Caspases, particularly caspase-3, contribute to contractile dysfunction by degrading myofibrillar proteins.
- Selective inhibition of caspase-3's proteolytic activity offers a promising therapeutic avenue for heart failure.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:24Caspases
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.